Changeflow GovPing Healthcare & Life Sciences Imidazopyridine-Pyrimidine Derivatives, Merck, ...
Routine Notice Added Final

Imidazopyridine-Pyrimidine Derivatives, Merck, Apr 15

Favicon for changeflow.com EPO Patent Bulletin - Therapeutics (A61P)
Published
Detected
Email

Summary

The EPO published European patent application EP4003992A1 for 4-(imidazo[1,2-a]pyridin-3-yl)-pyrimidine derivatives filed by Merck Patent GmbH. The A1 publication includes the European search report and designates all contracting states (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR). The IPC classification A61P 35/00 indicates the compounds are directed to anti-cancer therapeutic applications.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors EPO Patent Bulletin - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 24 changes logged to date.

What changed

The EPO published European patent application EP4003992A1 for 4-(imidazo[1,2-a]pyridin-3-yl)-pyrimidine derivatives filed by Merck Patent GmbH. The A1 publication includes the European search report and covers heterocyclic pharmaceutical compositions classified under C07D 471/04 and C07D 487/04, with therapeutic application A61P 35/00 (anti-cancer). The application designates all EPC contracting states.

Competitors developing heterocyclic anti-cancer compounds should review this application to assess potential overlap with their own programmes. Freedom-to-operate analyses may need to account for this publication as it establishes a priority date. Generic manufacturers targeting similar mechanisms should monitor prosecution to understand the scope of claims that may eventually issue.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES

Publication EP4003992A1 Kind: A1 Apr 15, 2026

Applicants

Merck Patent GmbH

Inventors

DORSCH, Dieter, BLUM, Andreas, BUCHSTALLER, Hans-Peter

IPC Classifications

C07D 471/04 20060101AFI20210129BHEP C07D 487/04 20060101ALI20210129BHEP A61K 31/506 20060101ALI20210129BHEP A61P 35/00 20060101ALI20210129BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 15th, 2026
Instrument
Notice
Branch
International
Legal weight
Non-binding
Stage
Final
Change scope
Substantive

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent application filing Pharmaceutical research Anti-cancer drug development
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Regulatory Affairs
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!